BIOV — BioVersys AG Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
- CH₣160.82m
- CH₣182.55m
- CH₣0.80m
Annual cashflow statement for BioVersys AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -18.3 | -18.7 | -21.8 |
| Depreciation | |||
| Non-Cash Items | 2.27 | 1.81 | 2.5 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 4.1 | 1.05 | -2.93 |
| Change in Prepaid Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -11.7 | -15.6 | -21.9 |
| Capital Expenditures | -0.049 | -0.038 | -0.216 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | 3.34 | -2 | 6 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | 3.29 | -2.04 | 5.78 |
| Financing Cash Flow Items | -0.022 | 4.73 | -6.94 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 7.13 | 19.2 | 72.6 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -2.19 | 2.24 | 55.9 |